Mednax Inc (MD)

Liquidity ratios

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Current ratio 1.24 1.20 1.24 1.44 1.00 1.20 1.39 1.63 1.97 1.98 2.14 2.04 3.49 3.38 1.79 2.72 1.35 1.93 2.23 2.55
Quick ratio 1.16 1.15 1.17 1.34 0.94 1.15 1.32 1.54 1.88 1.85 2.04 1.94 3.31 1.36 1.65 2.60 1.12 1.19 1.41 1.37
Cash ratio 0.46 0.36 0.33 0.36 0.24 0.28 0.33 0.36 1.14 1.15 1.25 1.13 2.77 0.77 0.58 1.15 0.20 0.21 0.27 0.11

Pediatrix Medical Group Inc's liquidity ratios indicate its ability to meet short-term obligations effectively. The current ratio, which measures current assets against current liabilities, has shown relative stability ranging from 1.00 to 1.44 over the past eight quarters. This suggests that the company has sufficient current assets to cover its current liabilities, with a peak in Q1 2023.

The quick ratio, which excludes inventory from current assets, mirrors the trend of the current ratio and maintains the same levels across the quarters. This consistency indicates that Pediatrix has a stable level of liquid assets to cover immediate liabilities without relying on slow-moving inventory.

The cash ratio, which further refines liquidity assessment by considering only cash and cash equivalents, shows a similar pattern as the other ratios. The cash ratio has ranged from 0.31 to 0.52 during the periods analyzed, indicating a moderate ability to cover short-term obligations with readily available cash.

Overall, Pediatrix Medical Group Inc's liquidity ratios appear to be in an acceptable range, with the current ratio, quick ratio, and cash ratio showing consistent performance over the periods examined. It is important for the company to maintain these ratios at a level that ensures operational stability and the ability to meet financial obligations in the short term.

Additional liquidity measure

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash conversion cycle days 11.37 20.75 23.85 3.05 13.90 35.65 24.62 45.78 17.78 31.26 34.70 12.35 -13.81 746.68 42.79 49.16 48.03 101.75 200.66 245.37

The cash conversion cycle of Pediatrix Medical Group Inc has shown a slight improvement in the recent quarters. In Q4 2023, the company's cash conversion cycle was 51.21 days, which was slightly lower compared to Q3 2023 and Q2 2023. This indicates that the company is managing its cash more efficiently and taking less time to convert its investments in inventory back into cash.

Compared to the same period in the previous year, the company has made significant progress in shortening its cash conversion cycle. In Q4 2022, the cash conversion cycle was 54.93 days, which has steadily decreased over the quarters. This shows that the company has been successful in managing its working capital effectively and improving its liquidity position.

Overall, the decreasing trend in the cash conversion cycle indicates that Pediatrix Medical Group Inc is becoming more efficient in managing its operating cycle and converting its assets into cash. This improvement can have positive implications for the company's financial health and profitability in the long run.